Leerink Swann Initiates Horizon Pharma With Outperform

Leerink Swann initiated coverage on

with a Outperform rating. The target price for Horizon Pharma is set to $37. Horizon Pharma shares have gained 126.97 percent over the past 52 weeks, while the S&P 500 index has surged 12.12 percent in the same period. Horizon Pharma shares fell 1.80 percent to $30.00 in after-hours trading.